Monoclonal Advantage Yurogen offers a platform to efficiently develop monoclonal antibodies from multiple host species, with a focus on rabbit, and a screening platform that shortens discovery timelines while delivering high-affinity antibodies.

Strategic Backing As a fully integrated ABclonal subsidiary since 2021, Yurogen benefits from corporate backing and potential cross-sell opportunities across ABclonal's product lines and global distribution.

Hub Proximity Located in the Greater Boston biotech hub, Yurogen has proximity to universities, research institutes, and CROs ideal for accelerating contract antibody services and co-development programs.

Mid-scale Opportunity With revenue around 10-25 million and a mid-sized team, there is clear potential to win mid-market biotech and diagnostic customers needing scalable production, high-volume screening, and cost-efficient custom antibodies.

Diversified Demand Its current emphasis on IVD and academic research antibodies signals room to expand into broader diagnostic tools and life-science instrument partnerships, including device manufacturers and core facilities seeking rabbit or multi-host antibodies.